Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
GlaxoSmithKline (GSK) is trading at $49.71, flat on the day. Its market value of $99.59B makes it the 159th largest of the 300 companies we follow.
The 52-week range is $38.98 to $60.12. Today's price is about 51% of the way from the low to the high. Holders are ahead 28.1% over twelve months, but down 1.8% across the last three months.
On the chart it has slipped under both the 50-day ($50.79) and 200-day ($51.65) moving averages; RSI is 50, and the last 30 sessions moved at roughly 25% annualized volatility.
For the quarter ended Jun 2026 it reported £8.41B in revenue, up 5.3% from a year earlier, with £553.00M of net profit (a 14.5% margin).
The stock changes hands at 15.9 times trailing earnings, 15% above its five-year average of 13.9. The median for its industry group is 20.4.
1 analysts follow the stock and the average call is "hold". The mean target, $70.00, sits 40.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
GSK is a British pharmaceutical company focused on vaccines, HIV medicines and specialty drugs, having spun out its consumer unit Haleon.
What tends to move it. Sales of Shingrix and its HIV drugs and the patent expiry of Dovato-related products matter, as does its late-stage pipeline.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -0.8% | Bearish |
| Price vs 50-day average | -2.1% | Bearish |
| Price vs 200-day average | -3.8% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 50.3 | Bullish |
| MACD (12,26,9) | -0.10 | Bullish |
| Bollinger band position | 40% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026 · reported in GBP
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 63rd percentile, 5-year average 13.9x
#1224 of 2974 stocks by PE (1 = cheapest)
Below its usual level · 30th percentile, 5-year average 4.7x
#4097 of 5302 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 80th percentile, 5-year average 2.1x
#2635 of 5141 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$2.53M (9 inflow days, 11 outflow days).
Across the full calendar years shown, the annual payout shrank by roughly 3.0% a year.
$49.71 is the latest print for GSK, a move of +0.00% against yesterday's close of $49.71. Today's low and high so far: $49.57 and $50.14.
Equity value comes to $99.59B at the current price. By that measure it is number 159 of the 300 names in our coverage.
Buyers pay 15.9 times the last twelve months of profit (EPS $3.68). Averaged over five years the multiple has been 13.9, and today's level ranks in the 63rd percentile of its own history.
The year's floor is $38.98 and the ceiling $60.12. Shares are 17.3% away from that ceiling.
It does. Payouts over the past twelve months work out to a 3.57% yield; the latest ex-dividend date was August 14, 2026.
Of 1 analysts, 0% say buy, 100% hold and 0% sell. Price targets average $70.00, with the most cautious at $70.00 and the most optimistic at $70.00.
GSK is a British pharmaceutical company focused on vaccines, HIV medicines and specialty drugs, having spun out its consumer unit Haleon.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.